Dr Carlos King Ho WONG

Assistant Professor
Department of Family Medicine and Primary Care

• BSc(HKUST), MPhil(HKUST), PhD(HKU)

	carlosho@hku.hk
	HKU Scholars Hub
	ORCiD Connecting Research and Researchers

Dr Carlos Wong is the Assistant Professor of the Department of Pharmacology and Pharmacy & Department of Family Medicine and Primary Care. He received PHD from the University of Hong Kong for his work on health-related quality of life of colorectal cancer and economic evaluation of colorectal cancer screening. Prior to his PhD, He graduated with Bachelor and MPhil degrees from Department of Mathematics at HK University of Science and Technology.

His research interests are patient-reported outcome measurement including quality of life, and health services research, particularly retrospective administrative database research and cost-effectiveness analysis of health care interventions. He has published more than 160 articles in peer-reviewed journals in field of quality of life, health economics, evaluation of primary and secondary care interventions. He is appointed as member of editorial board of journal 'The Patient - Patient-Centered Outcomes Research', and statistical advisor of 'Hong Kong Medical Journal'. He was awarded the Glasgow / HKU early career mobility fund to be visiting researcher at Health Economics and Health Technology Assessment (HEHTA), University of Glasgow in 2016, and was awarded the HMRF Research Fellowship in 2017 to be academic visitor at Health Economics Research Centre, University of Oxford in 2019.

Key Publications

Publication Highlights

• Wong, C.K.H.*, et al. Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study. Lancet 2022 [IF=202.731, JCR: 1/172 in Medicine, General & Internal, first and corresponding author]
• Wong, C.K.H.*, et al. Real-world effectiveness of early molnupiravir or nirmatrelvir/ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s Omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022, DOI: 10.1016/S1473-3099(22)00507-2 [IF=71.421, JCR: 2/94 in Infectious Diseases, first and corresponding author]
• Wong, C.K.H., et al. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines, Journal of Hepatology 2022, DOI: 10.1016/j.jhep.2022.06.032 [IF= 30.083, JCR: 5/93 in Gastroenterology & Hepatology, first author] 

 

Selected Publications

 

• Wong, C.K.H.*, et al. Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone, Clinical Infectious Diseases, 2021, DOI:10.1093/cid/ciab728 [IF=20.999, JCR: 18/162 in Immunology, 3/92 in Infectious Diseases, 12/137 in Microbiology, corresponding author and first author]
• Wong, C.K.H.*, et al. Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with COVID-19. Clinical Infectious Diseases 2022;74(8):1450-1458 DOI: 10.1093/cid/ciab631 [IF=20.999, JCR: 18/162 in Immunology, 3/92 in Infectious Diseases, 12/137 in Microbiology, corresponding author and first author]
• Tang, E.H.M., …, Wong, C.K.H.*, Lam, C.L.K. Ten-year effectiveness of multidisciplinary Risk Assessment and Management Programme - Diabetes Mellitus (RAMP-DM) on macrovascular, microvascular complications and all-cause mortality: A population-based cohort study. Diabetes Care 2022 [IF=17.152, co-corresponding author]
• Wong, C.K.H., et al. Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: a propensity-score analysis. EClinicalMedicine 2021;32:100743 [IF= 17.033, JCR: 12/172 in Medicine, General & Internal, co-first author]
• Lui, D.T.W., Au, I.C.H., … Wong, C.K.H.. Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis, EClinicalMedicine, 50, 101510. (2022), DOI: 10.1016/j.eclinm.2022.101510 [IF= 17.033, JCR: 12/172 in Medicine, General & Internal, corresponding author]
• Wong, C.K.H., et al. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study, PLoS medicine, 19(6), p.e1004018, DOI: 10.1371/journal.pmed.1004018 [IF=11.613, JCR: 20/167 in Medicine, General & Internal, co-first author]
• Wong, C.K.H., et al. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization. BMC Med 20, 119 (2022). DOI: 10.1186/s12916-022-02321-4 [IF=11.150, JCR: 21/172 in Medicine, General & Internal, co-first author]
• Liu, X., Wong, C.K.H., et al. Outcomes of Graves’ disease patients following anti-thyroid drugs, radioactive iodine or thyroidectomy as the first-line treatment. Annals of Surgery 2021;273(6):1197-1206.  [IF= 13.787, JCR= 2/211 in Surgery, co-first author] 
• Liu, X., Wong, C.K.H., et al. Long-term outcome of patients treated with antithyroid drugs, radioactive iodine or surgery for persistent or relapsed Graves’ disease, British Journal of Surgery 2022;109(4):381-389 [IF=11.122, JCR: 11/211 in Surgery, First author]
• Wu, T., ..., Wong, C.K.H., Bariatric surgery is expensive but improves comorbidity: Five-year assessment of patients with obesity and type 2 diabetes. British Journal of Surgery 2021;108(5):554-565  [IF=11.122, JCR: 11/210 in Surgery, corresponding author]